Soligenix Announces Recent Accomplishments And Second Quarter 2024 Financial Results #DefendYourHealth #SNGX https://lnkd.in/eU-kxN_6
Soligenix, Inc.
Biotechnology
Princeton, NJ 5,656 followers
We are a late-stage biopharmaceutical company focused on developing & commercializing products to treat rare diseases
About us
Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Our Specialized BioTherapeutics business segment is developing and commercializing HyBryte™ (SGX301 or synthetic hypericin) as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). With a successful Phase 3 study completed, regulatory approval and commercialization for this product is being advanced initially in the U.S. Development programs in this business segment also include expansion of synthetic hypericin (SGX302) into psoriasis, our first-in-class innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of inflammatory diseases, and proprietary formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention / treatment of gastrointestinal (GI) disorders characterized by severe inflammation, including pediatric Crohn's disease (SGX203). Our Public Health Solutions business segment includes active development programs for RiVax®, our ricin toxin vaccine candidate, and vaccine programs targeting both filoviruses (such as Marburg and Ebola) and coronaviruses (COVID-19; CiVax™). The development of our vaccine programs incorporates the use of our proprietary heat stabilization platform technology, known as ThermoVax®. We are also developing SGX943, our therapeutic candidate for antibiotic resistant and emerging infectious disease. To date, this business segment has been supported with government grant and contract funding from the National Institute of Allergy and Infectious Diseases (NIAID), the Biomedical Advanced Research and Development Authority (BARDA), and the Defense Threat Reduction Agency (DTRA).
- Website
-
http://www.soligenix.com
External link for Soligenix, Inc.
- Industry
- Biotechnology
- Company size
- 11-50 employees
- Headquarters
- Princeton, NJ
- Type
- Public Company
- Founded
- 1987
- Specialties
- biotechnology, oncology, rare disease, rare cancers, oral mucositis, Cutaneous T-Cell Lymphoma, ricin toxin vaccine, Pediatric Crohn’s disease, Head and neck cancer, Antibiotic resistant infectious disease, Photodynamic therapy, heat stable vaccines, Melioidosis, Hypericin, Ebola, Innate defense regulator, Infectious disease, Acute radiation enteritis, Ricin exposure, Acute radiation syndrome, Orphan diseases, and bioterrorism
Locations
-
Primary
29 Emmons Drive
Suite B-10
Princeton, NJ 08540, US
Employees at Soligenix, Inc.
Updates
-
Strong Clinical Support for Soligenix's HyBryte™ in Treating Cutaneous T-Cell Lymphoma; Exclusive Interview with Dr. Brian Poligone https://lnkd.in/ePTXhZej #DefendYourHealth #CTCL #clinicaltrials
Clinicians Back Soligenix's HyBryte™ for Cutaneous T-Cell Lymphoma; PCG Interview Dr. Brian Poligone
https://www.youtube.com/
-
Q&A with Dr. Ellen Kim, the Lead Principal Investigator for Soligenix’s Phase 3 FLASH study in CTCL: Soligenix's Hybryte: Lighting the Way Towards Commercial Success with Promising Flash Study Results https://lnkd.in/e5QFVxPS #Hybryte #DefendYourHealth #biotech #clinicaltrials
Soligenix's HyBryte™: Lighting the Way Towards Commercial Success with Promising FLASH Study Results
https://prismmarketview.com
-
Soligenix Announces Positive Clinical Results from a Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma - HyBryte™ demonstrates more rapid and robust treatment response compared to Valchlor® during 12-week treatment course - https://lnkd.in/dd9t5nnU #ctcl #positiveclinicalresults #defendyourhealth #biotech #clinicalstudy
-
Soligenix announces A Comparison of Vaccine Technologies to be Presented at the ASM Microbe Conference. Click to read more: https://lnkd.in/eHHtq8_n
A Comparison of Vaccine Technologies to be Presented at the ASM Microbe Conference
ir.soligenix.com
-
Learn more about Soligenix! #defendyourhealth #ctcl #psoriasis #biotech #sngx https://lnkd.in/ewx-AgPM
Soligenix Investor Overview
https://www.youtube.com/
-
LAST DAY TO VOTE! Participate in our Annual Meeting of Shareholders. Go to www.proxyvote.com or call 1-800-690-6903 (have your proxy card available) to vote. If you do NOT have your proxy card available, call our proxy solicitor, Alliance Advisors at 1-833-782-7145.
-
-
Soligenix Encourages Stockholders to Vote their Shares at the Annual Meeting #defendyourhealth #SNGX https://lnkd.in/eWZTBZDz
Soligenix Encourages Stockholders to Vote their Shares at the Annual Meeting
ir.soligenix.com
-
LAST 2 DAYS TO VOTE! Participate in our Annual Meeting of Shareholders. Go to www.proxyvote.com or call 1-800-690-6903 (have your proxy card available) to vote. If you do NOT have your proxy card available, call our proxy solicitor, Alliance Advisors at 1-833-782-7145.
Make your proxy vote count today.
east.proxyvote.com